Development of Liposomal Ciprofloxacin to Treat Lung Infections

Development of Liposomal Ciprofloxacin to Treat Lung Infections

Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowar...

Full description

Bibliographic Details
Main Authors: David Cipolla, Jim Blanchard, Igor Gonda
Format: Article
Language:English
Published: MDPI AG 2016-03-01
Series:Pharmaceutics
Subjects:
liposomes
formulation
ciprofloxacin
lung infection
cystic fibrosis
bronchiectasis
non-tuberculous mycobacteria
inhalation delivery
Online Access:http://www.mdpi.com/1999-4923/8/1/6

Internet

http://www.mdpi.com/1999-4923/8/1/6

Similar Items